Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1376304 | 1.00 | PPARG (0.51) | PPARGGPR132ACHEBACE1FFAR4 | |
| Adipic Acid SCHEMBL6760249 | 0.93 | FFAR1 (0.55) | PPARGGPR132ACHEBACE1FFAR4 | |
| SCHEMBL4732889 | 0.92 | ACHE (0.52) | PPARGGPR132ACHEBACE1NFKB1 | |
| SCHEMBL4732887 | 0.92 | ACHE (0.52) | PPARGGPR132ACHEBACE1NFKB1 | |
| SCHEMBL561406 | 0.84 | ACHE (0.49) | PPARGGPR132ACHEBACE1FFAR4 | |
| SCHEMBL649787 | 0.84 | ACHE (0.49) | PPARGGPR132ACHEBACE1FFAR4 | |
| SCHEMBL15287182 | 0.84 | ACHE (0.49) | PPARGGPR132ACHEBACE1FFAR4 | |
| SCHEMBL4759937 | 0.84 | ACHE (0.49) | PPARGGPR132ACHEBACE1FFAR4 | |
| SCHEMBL15286996 | 0.84 | ACHE (0.49) | PPARGGPR132ACHEBACE1FFAR4 | |
| SCHEMBL4745520 | 0.84 | ACHE (0.49) | PPARGGPR132ACHEBACE1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1353666-B1 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE | CLEVELAND CLINIC FOUNDATION (US) | 2013-07-03 | — | — | EP | claimed |
| US-20130102019-A1 | ASSESSING THE RISK OF A MAJOR ADVERSE CARDIAC EVENT IN PATIENTS WITH CHEST PAIN | THE CLEVELAND CLINIC FOUNDATION (US) | 2013-04-25 | — | — | US | claimed |
| US-8349581-B2 | Assessing the risk of a major adverse cardiac event in patients with chest pain | THE CLEVELAND CLINIC FOUNDATION (US) | 2013-01-08 | — | — | US | claimed |
| US-20110152224-A1 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2011-06-23 | — | — | US | claimed |
| US-20090061472-A1 | ASSESSING THE RISK OF A MAJOR ADVERSE CARDIAC EVENT IN PATIENTS WITH CHEST PAIN | THE CLEVELAND CLINIC FOUNDATION (US) | 2009-03-05 | — | — | US | claimed |
| US-7459286-B1 | Assessing the risk of a major adverse cardiac event in patients with chest pain | THE CLEVELAND CLINIC FOUNDATION (US) | 2008-12-02 | — | — | US | claimed |
| US-20080009020-A1 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2008-01-10 | — | — | US | claimed |
| EP-1495132-A4 | SYSTEMIC MARKER FOR MONITORING ANTI-INFLAMMATORY AND ANTIOXIDANT ACTIONS OF THERAPEUTIC AGENTS | CLEVELAND CLINIC FOUNDATION (US) | 2007-07-11 | — | — | EP | claimed |
| US-20060286106-A1 | Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents | THE CLEVELAND CLINIC FOUNDATION | 2006-12-21 | — | — | US | claimed |
| US-20060105408-A1 | determining total protein bound or total free levels or both of one or more myeloperoxidase (MPO)-generated amino acids in a bodily sample of blood, serum, plasma, or urine from the patient | THE CLEVELAND CLINIC FOUNDATION | 2006-05-18 | — | — | US | claimed |
| EP-1495132-A2 | SYSTEMIC MARKER FOR MONITORING ANTI-INFLAMMATORY AND ANTIOXIDANT ACTIONS OF THERAPEUTIC AGENTS | THE CLEVELAND CLINIC FOUNDATION (US) | 2005-01-12 | — | — | EP | claimed |
| EP-1353666-A4 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE | CLEVELAND CLINIC FOUNDATION (US) | 2004-03-31 | — | — | EP | claimed |
| WO-2003088814-A2 | SYSTEMIC MARKER FOR MONITORING ANTI-INFLAMMATORY AND ANTIOXIDANT ACTIONS OF THERAPEUTIC AGENTS | THE CLEVELAND CLINIC FOUNDATION (US) | 2003-10-30 | — | — | WO | claimed |
| EP-1353666-A2 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2003-10-22 | — | — | EP | claimed |
| US-20030180218-A1 | Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents | THE CLEVELAND CLINIC FOUNDATION | 2003-09-25 | — | — | US | claimed |
| US-20020164662-A1 | Myeloperoxidase, a risk indicator for cardiovascular disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-11-07 | — | — | US | claimed |
| WO-2002062207-A2 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2002-08-15 | — | — | WO | claimed |
| WO-2025245119-A1 | A NEW THERAPEUTIC APPROACH FOR TREATING ELEVATED LIPOPROTEIN (A) | RHODE ISLAND HOSPITAL (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20020164662-A1 | Myeloperoxidase, a risk indicator for cardiovascular disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-11-07 | — | — | US | disclosed |
| WO-2002062207-A2 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2002-08-15 | — | — | WO | disclosed |